Zavation Medical Products has announced that it has received US Food and Drug Administration (FDA) 510(k) clearance of its expandable lumbar interbody fusion cage, eZspand Lateral.
According to Zavation, the eZspand Lateral features unmatched expandable precision paired with continual expansion to provide an optimised fit for each patient. This optimised fit allows for enhancement of structural stability and improved sagittal balance.
The eZspand Lateral device does not require secondary locking, minimising procedural steps. The cage has up to 15° lordosis and the ability to back fill with bone graft. Each implant expands to 6mm from the insertion height to create a large graft window that facilitates fusion. The benefits of continuous height adjustment, up to 6mm expansion paired with no secondary locking step, separate eZspand Lateral from its competitors, add the company.
Jeffrey Johnson, chief executive officer of Zavation, said: “Our product development team’s dedication to creatively blending simplicity and precision in a robust product design has produced an expandable product that we believe is the new gold standard in facilitating patient fusion in a seamless and simplified procedure.
“With restoration of alignment being of critical importance, the eZspand Lateral was developed to help surgeons address stability and sagittal alignment, while maximising lordotic correction. This product is an example of Zavation’s commitment to offering innovative and differentiated products in conjunction with market leading customer service to best serve our surgeons and distributor network.”